ReviewFrontiers in oncology2026
Biliary microbiota and metabolic reprogramming in gallstone-associated gallbladder cancer: evidence from bile, stones, mucosa and tumor tissue.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder cancer (GBC) commonly arises in gallbladders affected by cholelithiasis and chronic cholecystitis, although malignancy develops in only a small minority of patients with stones. This disparity has directed attention to the local conditions created by concentrated bile, stone surfaces, persistent microbes and altered bile acid and lipid metabolism. Evidence in this field is difficult to compare because bile, stones, mucosa and tumor tissue measure different biological processes, while human associations, animal experiments and cross-sectional omics studies are often discussed together. We evaluated microbiological, metabolic and tissue-level studies according to the material examined, disease endpoint and study design, covering gallstone formation, chronic epithelial injury, preneoplastic lesions and established GBC. Salmonella is the most extensively studied microbial candidate, but epidemiological estimates vary with carrier prevalence, detection method and the use of gallstone controls. Fungal findings in GBC currently derive from one exploratory peptide-classification study, whereas separate fungal experiments concern gallstone formation. TMAO has reproducible effects on biliary cholesterol handling and lithogenesis; its relation to GBC is based on cross-sectional plasma measurements and preneoplastic histology in lithogenic-diet mice, without invasive cancer in that model. Single-cell and spatial studies identify epithelial stress, myeloid recruitment, T-cell exhaustion and stromal remodeling in sampled tissues, but precursor lesions remain sparse and pseudotime does not represent clinical follow-up. Bile lipidomics, microbial peptides and circulating markers may aid preoperative assessment when tested against inflammatory gallbladder disease. Distinguishing the material examined and the measured endpoint separates evidence for stone formation, persistent mucosal injury and established cancer, and identifies where paired bile, stone, mucosal and tumor samples can answer specific biological questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.